Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05915546 · ClinicalTrials.gov registry record · Phase 1
The Effect of Food on the Pharmacokinetics (PK) of Emraclidine in Healthy Adult Participants
A Phase 1 study, sponsored by Cerevel Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT05915546 is a Phase 1 study that has completed, run by Cerevel Therapeutics. The registered enrollment target is 16 participants.
The verdict
NCT05915546, a Phase 1 study, has completed, sponsored by Cerevel Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the effect of food (a high-fat meal) on the pharmacokinetics of emraclidine and metabolite CV-0000364 following single oral dose administration in healthy adult participants.
Interventions
- DRUG Emraclidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2023-06-08 |
| Est. Completion | 2023-07-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05915546
The ClinicalTrials.gov registry entry for NCT05915546 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cerevel Therapeutics, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Emraclidine is the first listed.
NCT05915546 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05915546 about?
NCT05915546 is a clinical study titled "The Effect of Food on the Pharmacokinetics (PK) of Emraclidine in Healthy Adult Participants". The primary purpose of this study is to evaluate the effect of food (a high-fat meal) on the pharmacokinetics of emraclidine and metabolite CV-0000364 following single oral dose administration in healthy adult participants.
What is the current status of trial NCT05915546?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2023-06-08. Estimated completion is 2023-07-26.
What interventions are being tested in trial NCT05915546?
The interventions under investigation include: Emraclidine (DRUG).
Who is sponsoring clinical trial NCT05915546?
This trial is sponsored by Cerevel Therapeutics, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.